electroCore’s Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards
electroCore (Nasdaq: ECOR) announced that its Truvaga™ Plus device has been awarded "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards. The handheld vagus nerve stimulation (nVNS) device was selected by Esquire's editors after extensive testing, recognized for its ability to promote relaxation and better sleep through two-minute sessions.
The device stands out for its drug-free approach to calming the nervous system, reducing stress, and enhancing sleep quality. This recognition in Esquire's annual Sleep Awards, which highlights the most effective sleep and recovery solutions, serves as third-party validation for consumers seeking alternative sleep improvement methods.
electroCore (Nasdaq: ECOR) ha annunciato che il suo dispositivo Truvaga™ Plus è stato premiato come «Miglior Gadget di Rilassamento» ai Sleep Awards 2025 di Esquire. Il dispositivo portatile per la stimolazione del nervo vago (nVNS) è stato selezionato dagli editor di Esquire dopo test approfonditi, riconosciuto per la capacità di favorire il rilassamento e un sonno migliore tramite sessioni di due minuti.
Il dispositivo si distingue per il suo approccio privo di farmaci per calmare il sistema nervoso, ridurre lo stress e migliorare la qualità del sonno. Questo riconoscimento, all’interno degli Sleep Awards annuali di Esquire che evidenziano le soluzioni più efficaci per dormire e recuperare, funge da validazione indipendente per i consumatori che cercano metodi alternativi per migliorare il sonno.
electroCore (Nasdaq: ECOR) anunció que su dispositivo Truvaga™ Plus recibió el premio "Mejor Gadget de Relajación" en las Sleep Awards 2025 de Esquire. El dispositivo de estimulación del nervio vago (nVNS) de mano fue seleccionado por los editores de Esquire tras pruebas exhaustivas, y reconocido por su capacidad para promover la relajación y un mejor sueño mediante sesiones de dos minutos.
El dispositivo destaca por su enfoque libre de fármacos para calmar el sistema nervioso, reducir el estrés y mejorar la calidad del sueño. Este reconocimiento en los Sleep Awards anuales de Esquire, que destacan las soluciones más eficaces para dormir y recuperarse, sirve como validación de terceros para los consumidores que buscan métodos alternativos para mejorar el sueño.
electroCore(Nasdaq: ECOR)가 Truvaga™ Plus 기기가 Esquire의 2025년 수면상에서 최고의 이완 도구로 선정되었다고 발표했습니다. 손에 쏙 들어오는 미주경신경 자극(nVNS) 기기는 Esquire 편집진의 광범위한 테스트 후 선정되었으며, 2분 세션으로 이완과 더 나은 수면을 촉진하는 능력으로 인정받았습니다.
이 기기는 약물 없이도 신경계를 차분하게 하고 스트레스를 줄이며 수면의 질을 향상시키는 접근 방식으로 돋보입니다. Esquire의 연례 수면상에서 수면과 회복에 가장 효과적인 솔루션으로 선정된 이 칭호는 대체적인 수면 개선 방법을 찾는 소비자들에게 제3자 검증으로 작용합니다.
electroCore (NASDAQ: ECOR) a annoncé que son appareil Truvaga™ Plus a reçu le prix « Meilleur gadget de relaxation » lors des Sleep Awards 2025 d'Esquire. Cet appareil portable de stimulation du nerf vague (nVNS) a été sélectionné par les rédacteurs d'Esquire après des tests approfondis, et reconnu pour sa capacité à favoriser la relaxation et un meilleur sommeil grâce à des sessions de deux minutes.
L'appareil se distingue par son approche sans médicament pour calmer le système nerveux, réduire le stress et améliorer la qualité du sommeil. Cette reconnaissance dans les Sleep Awards annuels d'Esquire, qui mettent en lumière les solutions les plus efficaces pour dormir et récupérer, constitue une validation indépendante pour les consommateurs recherchant des méthodes alternatives d'amélioration du sommeil.
electroCore (Nasdaq: ECOR) gab bekannt, dass sein Gerät Truvaga™ Plus den Preis „Bestes Relax-Gadget“ bei Esquires Sleep Awards 2025 gewonnen hat. Das tragbare Stimulationsgerät des Nervus vagus (nVNS) wurde von den Editoren von Esquire nach umfangreichen Tests ausgewählt und für seine Fähigkeit anerkannt, durch zwei-Minuten-Sitzungen Entspannung zu fördern und den Schlaf zu verbessern.
Das Gerät zeichnet sich durch seinen medikamentenfreien Ansatz zur Beruhigung des Nervensystems, zur Reduzierung von Stress und zur Steigerung der Schlafqualität aus. Diese Anerkennung bei Esquires jährlichen Sleep Awards, die die wirksamsten Schlaf- und Erholungs-Lösungen hervorheben, dient als unabhängige Bestätigung für Verbraucher, die nach alternativen Methoden zur Schlafverbesserung suchen.
electroCore (بورصة ناسداك: ECOR) أعلن أن جهازه Truvaga™ Plus قد فاز بجائزة «أفضل أداة للاسترخاء» في جوائز النوم Esquire 2025. تم اختيار جهاز التحفيز العصبي المبهم باليد (nVNS) من قبل محرري Esquire بعد اختبارات موسّعة، معترف به لقدراته في تعزيز الاسترخاء ونوم أفضل من خلال جلسات لمدة دقيقتين.
يبرز الجهاز لنهجه الخالي من الأدوية لتهدئة الجهاز العصبي وتقليل التوتر وتحسين جودة النوم. يمثل هذا التقدير في جوائز النوم السنوية من Esquire، التي تسلط الضوء على أكثر حلول النوم فاعلية، اعتماداً من طرف ثالث للمستهلكين الذين يبحثون عن طرق تحسين النوم البديلة.
electroCore (纳斯达克股票代码：ECOR) 宣布，其设备 Truvaga™ Plus 已获颁 Esquire 2025 睡眠奖“最佳放松小工具”奖。该手持迷走神经刺激设备（nVNS）经 Esquire 编辑部在广泛测试后遴选，因其通过两分钟的使用时段促进放松和更好的睡眠而获得认可。
该设备以无药物、安抚神经系统、降低压力、提升睡眠质量的选之方法而脱颖而出。Esquire 每年颁发的睡眠奖聚焦于最有效的睡眠与恢复解决方案，这一认可对寻求替代睡眠改善方法的消费者提供了第三方验证。
- Recognition in Esquire's 2025 Sleep Awards adds credibility to the Truvaga Plus product
- Third-party validation from independent editorial team may help drive consumer adoption
- None.
ROCKAWAY, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its Truvaga™ Plus handheld vagus nerve stimulation (nVNS) device has been named the “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards.
The annual Sleep Awards from Esquire recognize the most effective and innovative solutions for improving rest and recovery. Truvaga Plus was selected by the magazine’s editors after extensive hands-on testing, earning recognition for its ability to calm the nervous system, reduce stress, and promote restorative sleep in just two-minute sessions.
“We are honored to be recognized in Esquire’s Sleep Awards,” said Kelly Benning, Senior Vice President of Truvaga at electroCore. “This recognition is a powerful validation for Truvaga Plus. Sleep is one of the most universal health challenges people face, and having an independent editorial team highlight our device builds confidence for consumers seeking a proven, drug-free way to relax, recharge, and sleep better.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
About Truvaga Plus
Truvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company’s proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease.
- Backed by 20+ years of research in bioelectronic medicine
- Made in the USA and Shipped from the USA
- Drug-free and non-invasive technology for stress relief and sleep
- Quick two-minute sessions that fit easily into daily routines
- 30-Day risk-free trial available at www.truvaga.com
Truvaga Plus stands out as one of the few consumer wellness devices that leverages vagus nerve stimulation science, offering a natural alternative to medications and supplements for relaxation and sleep.
For more information on Truvaga Plus, or to purchase directly, visit www.truvaga.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the anticipated results from being Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards, the benefits of Truvaga Plus, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
ECOR Media Relations
(973) 435-8354
media-inquiries@electrocore.com
FAQ
What award did electroCore's Truvaga Plus receive in 2025?
How does the Truvaga Plus device from electroCore (ECOR) work?
What are the main benefits of electroCore's Truvaga Plus device?
Who selected Truvaga Plus for the Esquire Sleep Award?
